Loading company…
RegCell develops regulatory T cell (Treg) therapies aimed at controlling immune responses in autoimmune disease and cancer.
Based in Japan and founded in 2016, RegCell develops immune system control technologies built on regulatory T cells (Tregs). Its therapies target autoimmune diseases, cancer and transplant rejection, and the company targets healthcare providers, research institutions and pharmaceutical companies in Japan, the United States and Europe. In September 2026 the company raised USD 44 million in Series A funding led by Playground Global, LLC, with Global Brain, Mitsui Chemicals, LG Technology Ventures and other investors participating. The funds are planned for autoimmune disease treatment development.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in